Hidalgo-Tenorio, CarmenPasquau, JuanVinuesa, DavidFerra, SergioTerrón, AlbertoSanJoaquín, IsabelPayeras, AntoniMartínez, Onofre JuanLópez-Ruz, Miguel ÁngelOmar, Mohamedde la Torre-Lima, JavierLópez-Lirola, AnaPalomares, JesúsBlanco, José RamónMontero, MartaGarcía-Vallecillos, Coral2023-05-032023-05-032022-03-04http://hdl.handle.net/10668/21599Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log10, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VLenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/DOLAVIHIVdolutegravirlamivudinereal-world dataAdultAnti-HIV AgentsDrug Therapy, CombinationFemaleHIV InfectionsHIV SeropositivityHIV-1Heterocyclic Compounds, 3-RingHomosexuality, MaleHumansLamivudineMaleOxazinesPiperazinesPyridonesSexual and Gender MinoritiesViral Loadresearch article35336931open access10.3390/v140305241999-4915PMC8951045https://www.mdpi.com/1999-4915/14/3/524/pdf?version=1646372407https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951045/pdf